Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BRAIN Biotech AG (BNN.DE)
Zwingenberg, DE
Headquartered in Zwingenberg, Germany, and founded in 1993, BRAIN Biotech AG (renamed from B.R.A.I.N. Biotechnology Research and Information Network AG in April 2021) specializes in the discovery, development, production, and commercialization of advanced biological solutions. These include enzymes, biocatalysts, microorganisms, and naturally derived active compounds, catering to the chemical industry across Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two distinct segments: BioScience and BioIndustrial. The BioScience division is dedicated to uncovering and developing bioactive natural ingredients, such as sugar alternatives, taste modifiers, and other nature-based active components for diverse applications in the food, animal nutrition, skincare, cosmetics, and broader chemical sectors. Concurrently, the BioIndustrial segment focuses on identifying and optimizing enzymes and biocatalysts critical for manufacturing food and beverages, medical wound care products, lubricants, as well as for starch processing and bioethanol production. This segment also engineers microorganisms to serve as functional biomass for optimizing industrial manufacturing processes, converting greenhouse gas CO2 into a valuable industrial raw material, and facilitating the extraction of precious and rare earth metals. Furthermore, BRAIN Biotech AG has established strategic alliances with AnalytiCon Discovery GmbH and Roquette to jointly develop natural sweeteners and enhanced sweet taste solutions.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.06% | -8.33% | +11.24% | +16.93% | -4.81% | +14.67% | +42.11% | -39.26% | -70.88% | -65.14% | -67.36% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-9.2% Q1'26: -5.3% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-5.9% Q1'26: -14.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-24.7% Q1'26: -46.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-18.7% Q1'26: -18.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-47.5% Q1'26: +208.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-5.77× Q1'26: -1.30× (vs Q1'25)
| Metric |
Sep 2016 actual |
Sep 2017 actual |
Sep 2018 actual |
Sep 2019 actual |
Sep 2020 actual |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 3 Rev. Ana. 2 EPS Ana. |
Sep 2027 4 Rev. Ana. 2 EPS Ana. |
Sep 2028 2 Rev. Ana. 1 EPS Ana. |
Sep 2029 1 Rev. Ana. 1 EPS Ana. |
Sep 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
22.79M
est: 25.62M (-11.0%)
|
24.11M
est: 27.51M (-12.4%)
|
27.05M
est: 28.37M (-4.6%)
|
38.56M
est: 35.92M (+7.4%)
|
38.23M
est: 41.29M (-7.4%)
|
38.39M
est: 39.29M (-2.3%)
|
49.51M
est: 50.23M (-1.4%)
|
55.34M
est: 56.27M (-1.7%)
|
54.63M
est: 58.00M (-5.8%)
|
49.62M
est: 56.64M (-12.4%)
|
56.38M
53.46M – 61.76M
-0.5% YoY
|
67.47M
57.56M – 74.98M
+19.7% YoY
|
59.51M
57.14M – 61.88M
-11.8% YoY
|
66.67M
59.78M – 73.61M
+12.0% YoY
|
74.91M
67.17M – 82.71M
+12.4% YoY
|
| EBITDA |
-12.64M
est: -817.0K (-1,446.5%)
|
-7.59M
est: -13.73M (+44.7%)
|
-5.11M
est: -7.83M (+34.7%)
|
-5.71M
est: -4.51M (-26.7%)
|
-2.78M
est: -9.47M (+70.7%)
|
2.01M
est: -10.55M (+119.1%)
|
-1.30M
est: -12.24M (+89.4%)
|
-1.98M
est: -1.92M (-2.9%)
|
-4.23M
est: -1.98M (-113.9%)
|
-4.17M
est: -1.93M (-115.4%)
|
-1.93M
-2.11M – -1.83M
+0.5% YoY
|
-2.30M
-2.56M – -1.97M
-19.7% YoY
|
-2.03M
-2.11M – -1.95M
+11.8% YoY
|
-2.28M
-2.51M – -2.04M
-12.0% YoY
|
-2.56M
-2.83M – -2.29M
-12.4% YoY
|
| EBIT |
-14.08M
est: -3.21M (-338.4%)
|
-9.08M
est: -14.73M (+38.3%)
|
-8.02M
est: -9.96M (+19.5%)
|
-8.64M
est: -11.91M (+27.5%)
|
-6.71M
est: -8.07M (+16.8%)
|
-2.00M
est: -8.99M (+77.8%)
|
-5.64M
est: -10.43M (+46.0%)
|
-6.63M
est: -7.19M (+7.7%)
|
-9.05M
est: -7.39M (-22.4%)
|
-9.29M
est: -7.24M (-28.4%)
|
-7.20M
-7.89M – -6.83M
+0.5% YoY
|
-8.62M
-9.58M – -7.35M
-19.7% YoY
|
-7.60M
-7.91M – -7.30M
+11.8% YoY
|
-8.52M
-9.40M – -7.64M
-12.0% YoY
|
-9.57M
-10.57M – -8.58M
-12.4% YoY
|
| Net Income |
-14.69M
est: -10.37M (-41.7%)
|
-9.61M
est: -15.67M (+38.7%)
|
-8.28M
est: -10.21M (+18.9%)
|
-10.50M
est: -9.86M (-6.5%)
|
-9.68M
est: -11.78M (+17.8%)
|
-4.97M
est: -13.13M (+62.1%)
|
-6.59M
est: -15.23M (+56.7%)
|
-8.28M
est: -8.04M (-2.9%)
|
-11.13M
est: -3.10M (-259.1%)
|
-11.74M
est: -4.55M (-157.9%)
|
-5.96M
-6.00M – -5.92M
-31.0% YoY
|
351.5K
321.9K – 381.1K
+105.9% YoY
|
-5.44M
-5.72M – -4.36M
-1,647.8% YoY
|
-1.57M
-1.78M – -1.36M
+71.2% YoY
|
3.91M
3.39M – 4.44M
+349.5% YoY
|
| SGA |
4.49M
est: 2.22M (+102.4%)
|
3.23M
est: 24.45M (-86.8%)
|
4.05M
est: 20.89M (-80.6%)
|
3.66M
est: 23.10M (-84.1%)
|
3.33M
est: 23.44M (-85.8%)
|
2.72M
est: 26.11M (-89.6%)
|
4.30M
est: 30.30M (-85.8%)
|
5.38M
est: 5.46M (-1.4%)
|
4.97M
est: 5.61M (-11.4%)
|
6.91M
est: 5.49M (+25.7%)
|
5.47M
5.19M – 5.99M
-0.5% YoY
|
6.55M
5.58M – 7.27M
+19.7% YoY
|
5.77M
5.54M – 6.00M
-11.8% YoY
|
6.47M
5.80M – 7.14M
+12.0% YoY
|
7.27M
6.52M – 8.02M
+12.4% YoY
|
| EPS |
-0.97
est: -0.47 (-104.4%)
|
-0.58
est: -0.33 (-78.4%)
|
-0.46
est: -0.35 (-32.1%)
|
-0.58
est: -0.42 (-38.9%)
|
-0.52
est: -0.43 (-21.7%)
|
-0.25
est: -0.32 (+23.0%)
|
-0.30
est: -0.27 (-10.1%)
|
-0.38
est: -0.37 (-3.2%)
|
-0.51
est: -0.14 (-259.8%)
|
-0.54
est: -0.21 (-159.3%)
|
-0.27
-0.27 – -0.27
-31.0% YoY
|
0.02
0.01 – 0.02
+105.9% YoY
|
-0.23
-0.26 – -0.20
-1,534.1% YoY
|
-0.07
-0.08 – -0.06
+68.9% YoY
|
0.18
0.15 – 0.20
+349.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Adriaan Moelker | Chairman of the Management Board & Chief Executive Officer | 620.0K | male |
| Jurgen Eck | Consultant | 392.0K | — |
| Johan Jansen-Storbacka | Executive Vice President of BRAIN Biocatalysts enzyme products business | — | male |
| Martin Langer | MD & Executive Vice President | — | — |
| Michael Schneiders | Chief Financial Officer & Member of Management Board | — | male |
| Robbert Michael Hoekstra | Head of Group Finance | — | male |
| Ulrich Putsch | Co-Founder | — | male |
| Ute Dechert | Vice President of Human Resources & Processes | — | — |
| Alexander Pelzer | Vice President and Head of Research & Development - Zwingenberg | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BNN.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
